In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.VISIT NEW SITE
Creso Pharma appoints David Russell as Chief Operating Officer
1 minute read
Leading ASX listed medical cannabis group Creso Pharma (ASX:CPH) announced on Tuesday that it had appointed highly experienced pharmaceutical and biotech industry professional David Russell as its Chief Operating Officer.
Mr Russell has more than 25 years’ experience within the pharmaceutical and biotech industry with a number of leading global companies including Roche, Actelion Pharmaceuticals, Celgene and Novogen (ASX: NRT) .
Based in Sydney, Mr Russell will be responsible for assisting Creso’s CEO, Dr Miri Halperi Wernli, with the Company’s overall business and corporate strategy. He will also be responsible for developing the Australian business and the overall commercial strategy for the Company in Australia.
It should be noted here that Creso is still in its early stages and investors should seek professional financial advice if considering this stock for their portfolio.
Mr Russell has been responsible for building, leading and growing commercial teams resulting in multiple product launches in China, Australia and Asia in therapeutic areas covering haematology, oncology, immunology, cardiology and pulmonary medicine.
Mr Russell was also a Global Brand Leader for Swiss based biopharmaceutical company, Actelion Pharmaceuticals where he was responsible for its expansion into Asia and China.
In the past three years, Mr Russell has completed multiple projects for multinational clients including market entry strategies, product launches and distribution and logistics contracts.
Mr Russell said: “I’m excited to be joining Creso at this groundbreaking time for the medical cannabis industry. Creso is in a strong strategic position to ensure patients and consumers can benefit from the improving regulatory environment.”